This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These include innovations in biotechnology, the expansion of biosimilar medicines and increasing investment in research and development. Ultimately, the report stated that the demand is being initiated through an increasing incidence of chronic health conditions, such as cancer, diabetes, cardiovascular conditions and autoimmune disorders.
Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. The global obesity market faces supply issues, prompting Chinese pharma companies to leverage the situation to develop GLP-1 biosimilars.
This partnership is set to enhance the treatment options available to diabetes patients in Brazil. It develops, manufactures and commercialises complex biotech and biosimilar drug products at its production facility in Nova Lima. million cases by 2030, according to the Diabetes Atlas of the International Diabetes Federation (IDF).
Children and young people (CYP) living in low- and middle-income countries (LMICs) face gross inequities when it comes to the diagnosis and treatment of type 1 diabetes (T1D). Without sustainable access to diabetes care, they are unable to manage this chronic condition, leading to severe outcomes that are entirely preventable.
Another patient shared their journey with diabetes. As for the future of PGHD, many panelists were asked how they envision use of PGHD in 2030. This patient had used wearable devices on their own in the past but did not understand how to use the data to manage their health.
The Healthy People 2030 initiative addresses structural health care inequalities and implements programs to ameliorate SDOH. They are also more likely to have diabetes, pain, and disability than other groups. Healthy People 2030. 11 STEPPING UP A LEVEL Pharmacy teams can also speak to and for their communities. REFERENCES 1.
With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 4 Nononcology applications are growing, however, particularly for conditions such as osteoarthritis, type 1 diabetes, and Parkinson disease.
2019;380:2020-2030. Global Initiative for Asthma. Accessed June 9, 2025. Beasley R, Holliday M, Reddell HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med.
And now, biosimilars are being developed in India and China, which will hopefully make vaccination more affordable and accessible globally, or at least that’s the hope when we look at the data.” The World Health Organization (WHO) has set a global goal to have 90% of girls fully vaccinated with the HPV vaccine by 2030.
million deaths in 2019, and this is predicted to increase to approximately 23 million annual deaths by 2030. Omega-3 fatty acids effects on inflammatory biomarkers and lipid profiles among diabetic and cardiovascular disease patients: a systematic review and meta-analysis. 1 CVDs are disorders affecting the heart and blood vessels.
old, for use by women with diabetes who are pregnant & for wear time of up to 15 days. of revenue in 2023 from its four in-line therapies & bringing Pfizer $10B+ in risk-adjusted revenues by 2030. The results also showed a reduction in risk of hospitalization for any cause with 14% relative risk reduction (24.8
While India was able to leverage the 2008 patent cliff of small molecules, the same playbook will not work for biologics and biosimilars. Many biopharma companies in India have already leveraged the biosimilar patent cliff. Biocon became the first company from India to launch its biosimilar Hulio in the US in July 2023.
Robert Barrie July 4, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Only 4% of global drugs sales in 2030 will have patent protection. A recent report by GlobalData projects that the share of global drug sales under patent protection will decline by 2030. LanKS via Shutterstock.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content